Olema Oncology Engages Investors through Upcoming Conferences
Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", NASDAQ: OLMA), a leading clinical-stage biopharmaceutical company, is dedicated to revolutionizing treatment options for breast cancer and other diseases. They are excited to announce their participation in several significant investor conferences.
Scheduled Investor Conferences
Throughout the upcoming months, Olema Oncology will feature in a series of important events designed for investors, providing them with insights into the company's groundbreaking work in targeted therapies. Here are the details of the events:
Citi's 2025 Biopharma Back to School Conference
This conference will take place on September 2, 2025, at 4 p.m. ET. Olema will be involved in a fireside chat format, offering attendees an intimate look at their operations and future goals.
Wells Fargo 2025 Healthcare Conference
On September 3, 2025, starting at 3:45 p.m. ET, Olema will present their advancements in research and therapy development at this important healthcare gathering.
Cantor Global Healthcare Conference 2025
Following this, on September 4, 2025, at 11:30 a.m. ET, Olema will again participate in a fireside chat session, engaging with investors and discussing their innovative approaches.
Morgan Stanley's 23rd Annual Global Healthcare Conference
On September 8, 2025, at 10 a.m. ET, company representatives will share insights during another fireside chat, highlighting their commitment to improving patient outcomes.
H.C. Wainwright's 27th Annual Global Investment Conference
Lastly, Olema will conclude their busy conference schedule on September 9, 2025, at 9:30 a.m. ET with a fireside chat, further discussing their pipeline of promising therapies.
Availability of Presentations
For those unable to attend, live webcasts and recordings of the presentations will be accessible in the Events and Presentations section of Olema's investor relations website. This accessibility ensures that everyone has the opportunity to stay informed about Olema's advancements.
Overview of Olema Oncology
As a pioneering clinical-stage biopharmaceutical firm, Olema Oncology is focused on enhancing the landscape of breast cancer treatment. They are developing a robust pipeline of innovative therapies, leveraging extensive knowledge of endocrine-driven cancers and their resistance mechanisms. Their lead product candidate, palazestrant (OP-1250), stands out as a unique oral complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD), currently progressing through a Phase 3 clinical trial known as OPERA-01. Furthermore, Olema is making strides with another candidate, OP-3136, a potent inhibitor now in Phase 1 trials.
Contact Information for Media and Investors
For inquiries related to media or investor relations, please contact:
Courtney O'Konek
Vice President, Corporate Communications
Olema Oncology
Email: media@olema.com
Frequently Asked Questions
1. What is Olema Oncology's main focus?
Olema Oncology is dedicated to developing targeted therapies for breast cancer and improving patient outcomes through innovative treatments.
2. What are some upcoming conferences where Olema will participate?
Olema will be featured in conferences such as Citi's Biopharma Back to School, Wells Fargo Healthcare, and H.C. Wainwright's Investment Conference.
3. How can I access Olema's presentations from the conferences?
Presentations will be available via live webcasts and recordings on Olema's investor relations website.
4. What is palazestrant (OP-1250)?
Palazestrant is Olema's lead candidate, designed to act as a complete estrogen receptor antagonist and selective ER degrader, currently in a Phase 3 trial.
5. Who should I contact for more information regarding investor relations?
For investor inquiries, contact Courtney O'Konek via email at media@olema.com.
